Newer fluoroquinolones for treating respiratory infection: Do they mask tuberculosis?

European Respiratory Journal

Volumn 35, Issue 3, 2010, Pages 606-613

  Chang, K C ^a   Leung, C C ^a   Yew, W W ^a   Lau, T Y ^a   Leung, W M ^a   Tam, C M ^a   Lam, H C ^a   Tse, P S ^a   Wong, M Y ^a   Lee, S N ^a   Wat, K I ^a   Ma, Y H ^a  

^a GRANTHAM HOSPITAL   (Hong Kong)

Author keywords

Fluoroquinolones; Tuberculosis

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CIPROFLOXACIN; MOXIFLOXACIN; QUINOLONE DERIVATIVE;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; BRONCHIECTASIS; CHILL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOGLYCEMIA; IRRITABILITY; LOG RANK TEST; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MASKING; MUSCLE TWITCH; PLEURA EFFUSION; PNEUMONIA; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SIDE EFFECT; SLURRED SPEECH; TUBERCULOSIS;

AGED; ANTI-BACTERIAL AGENTS; BRONCHIECTASIS; COMMUNITY-ACQUIRED INFECTIONS; DELAYED DIAGNOSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROQUINOLONES; HUMANS; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PNEUMONIA, BACTERIAL; PROSPECTIVE STUDIES; SPUTUM; TUBERCULOSIS, PULMONARY;

EID: 77951195737     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00104209     Document Type: Article

References (30)

1. Lode H, Garau J. Improving care for patients with respiratory tract infections. J Chemother 2002; 14: Suppl. 2, 22-28. (Pubitemid 34297846)
2. Tillotson GS. Role of gemifloxacin in community-acquired pneumonia. Expert Rev Anti Infect Ther 2008; 6: 405-418.
3. Miravitlles M, Anzueto A. Moxifloxacin: a respiratory fluoroquinolone. Expert Opin Pharmacother 2008; 9: 1755-1772.
4. Vardakas KZ, Siempos II, Grammatikos A, et al. Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials. CMAJ 2008; 179: 1269-1277.
5. Petitpretz P, Arvis P, Marel M, et al. Oral moxifloxacin vs. high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults. Chest 2001; 119: 185-195.
6. Torres A, Muir JF, Corris P, et al. Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia. Eur Respir J 2003; 21: 135-143.
7. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44: Suppl. 2, S27-S72.
8. Yew WW, Chan CK, Chau CH, et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin- containing regimens. Chest 2000; 117: 744-751.
9. Yew WW, Chan CK, Leung CC, et al. Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong. Chest 2003; 124: 1476-1481.
10. Chan ED, Laurel V, Strand MJ, et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2004; 169: 1103-1109.
11. Leimane V, Riekstina V, Holtz TH, et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 2005; 365: 318-326.
12. Rustomjee R, Lienhardt C, Kanyok T, et al. A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2008; 12: 128-138.
13. Conde MB, Efron A, Loredo C, et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 2009; 373: 1183-1189.
14. Dooley KE, Golub J, Goes FS, et al. Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clin Infect Dis 2002; 34: 1607-1612. (Pubitemid 34615446)
15. Tuberculosis and Chest Service of the Dept of Health. Annual Report 2007. The Government of Hong Kong SAR.
16. Mandell LA, File TMJ. Short-course treatment of community-acquired pneumonia. Clin Infect Dis 2003; 37: 761-763.
17. Cohen J. Statistical Power Analysis for the Behavioral Sciences. Rev. Edn. New York, Academic Press, 1977.
18. Ko FWS, Lam RKY, Li TST, et al. Sputum bacteriology in patients hospitalized with acute exacerbations of chronic obstructive pulmonary disease and concomitant pneumonia in Hong Kong. Intern Med J 2005; 35: 661-667.
19. Wang J, Hsueh P, Jan I, et al. Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas. Thorax 2006; 61: 903-908.
20. Rothman KJ. Epidemiology: An Introduction. New York, Oxford University Press, Inc., 2002.
21. Gaba PD, Haley C, Griffin MR, et al. Increasing outpatient fluoroquinolone exposure before tuberculosis diagnosis and impact on culture-negative disease. Arch Intern Med 2007; 167: 2317-2322.
22. Long R, Chong H, Hoeppner V, et al. Empirical treatment of community-acquired pneumonia and the development of fluoroquinolone-resistant tuberculosis. Clin Infect Dis 2009; 48: 1354-1360.
23. Ginsburg AS, Grosset JH, Bishai WR. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis 2003; 3: 432-442.
24. Ginsburg AS, Hooper N, Parrish N, et al. Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Infect Dis 2003; 37: 1448-1452. (Pubitemid 37494671)
25. Huang T, Kunin CM, Shin-Jung Lee S, et al. Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre: 1995-2003. J Antimicrob Chemother 2005; 56: 1058-1062.
26. Drlica K, Zhao X. Mutant selection window hypothesis updated. Clin Infect Dis 2007; 44: 681-688.
27. Gumbo T, Louie A, Deziel MR, et al. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J Infect Dis 2004; 190: 1642-1651.
28. Johnson JL, Hadad DJ, Boom WH, et al. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2006; 10: 605-612.
29. Low DE. Fluoroquinolones for treatment of community-acquired pneumonia and tuberculosis: putting the risk of resistance into perspective. Clin Infect Dis 2009; 48: 1361-1363.
30. Devasia RA, Blackman A, Gebretsadik T, et al. Fluoroquinolone resistance in M. tuberculosis: the effect of duration and timing of fluoroquinolone exposure. Am J Respir Crit Care Med 2009; 180: 365-370.